Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AbCellera enters antibody discovery collaboration in neurology with Denali

March 1, 2019

FDA allows initiation of phase I study of CT-044

March 1, 2019

Theranexus presents preliminary results of phase II study of THN-102 on patients with narcolepsy

March 1, 2019

Sarepta Therapeutics announces preliminary results from first cohort in phase I/II study of MYO-101

Feb. 28, 2019

Immunic initiates phase II study of IMU-838 for relapsing-remitting MS

Feb. 27, 2019

Prion protein-binding monoclonal antibodies synthesized at New York University

Feb. 27, 2019

Imbrium Therapeutics and TetraGenetics collaborate to develop novel biologic therapeutics for pain

Feb. 27, 2019

Favorable interim phase I results for SRK-015 support progression to phase II for SMA

Feb. 26, 2019

Goldfinch Biopharma discloses TrpC5 antagonists

Feb. 26, 2019

The ties that bind synapses

Feb. 26, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 26, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma
BioWorld Science
Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...